In a recent post, we shared endocrinologist Gianluca Iacobellis’, MD, Ph.D. suggesting that DPP-4 inhibitors could help decrease COVID-19-related immune overreaction in people with diabetes.
However, according to Daniel Drucker, MD, Ph.D., there is “insufficient evidence” that DPP-IVs decrease the immune response during COVID-19 infections.
Daniel Drucker, MD, Ph.D., professor of medicine at the Lunenfeld Tanenbaum Research Institute of Mount Sinai Hospital and the University of Toronto and expert in the field, summarized that DPP-4 inhibitors and GLP-1 receptor agonists have not been associated with improved outcomes in critically ill individuals with diabetes and a COVID- 19 infection.
Insulin is the glucose-lowering therapy of choice for acute coronavirus-related illness in hospital.
Daniel Drucker, MD, Ph.D
Dr. Drucker states that available evidence does not currently support clinically meaningful alterations in markers of immune function after administration of DPP-IV inhibitors in humans with or without type 2 diabetes.
This is important news as it clears up medication misconceptions and further highlights the importance of administering insulin for people with type 2 diabetes and active COVID-19 infection.
Considering the fact that people with type 2 diabetes have a higher chance of developing complications from COVID-19 than people without diabetes, it is critical to use the most effective method of treatment.
Read More
- For more information on DPP4-Inhibitors, click here.
- To read our previous article about DPP-4 Inhibitors, click here.
